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EDITORIAL  COMMENT
Charcot-Marie-Tooth (CMT) disorders are an
extremely heterogeneous group of diseases of the
peripheral nervous system in humans, with a prevalence
of around 1 in 2,500.1 To date, mutations in 30 genes
have been reported in various CMT forms. In numerous
CMT types, only the locus is known, but some CMT
forms were shown not to be linked with any known
locus. Genetic studies in CMT disorders cover a wide
spectrum of problems ranging from identification of
novel mutations through studies of the pathogenic
nature of mutations to genotype–phenotype
correlations.
CMT type 1 (CMT1) is a genetically heterogeneous
group of chronic demyelinating polyneuropathies
with loci mapping to chromosome 17 (CMT1A),
chromosome 1 (CMT1B), chromosome 16 (CMT1C),
and chromosome 10 (CMT1D). CMT1A is most
often associated with a tandem 1.5-megabase (Mb)
duplication in chromosome 17p11.2-p12. Rarely, it
may result from a point mutation in the peripheral
myelin protein-22 (PMP22) gene. CMT1B is
associated with point mutations in the myelin protein
zero (Po or MPZ) gene. Mutations in the SIMPLE
gene cause CMT1C, and CMT1D is the result of
mutations in the early response 2 (ERG2 or Krox-20)
gene. An X-linked form of CMT1 (CMT1X) maps to
Xq13 and is associated with mutations in the
connexin32 (Cx32) gene. CMT neuropathy type 2
(CMT2) is an axonal neuropathy that maps to
chromosome 1p35-p36 (CMT2A), chromosome
3q13-q22 (CMT2B), chromosome 7p14 (CMT2D),
chromosome 8p21 (CMT2E), chromosome 1q22-
q23 (CMT2F), or chromosome 3q13 (CMT2G).
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Dejerine-Sottas disease (DSD), also called hereditary
motor and sensory neuropathy type III (HMSNIII), is
a severe, infantile-onset demyelinating polyneuropathy
syndrome that may be associated with point mutations
in either the PMP22 gene, PO gene, EGR2 gene or
the PRX gene (for the recessive form). It shares
considerable clinical and pathologic features with
CMT1. Hereditary neuropathy with liability to pressure
palsies (HNPP) is an autosomal dominant disorder
that results in a recurrent, episodic demyelinating
neuropathy. HNPP is associated with a 1.5-Mb deletion
in chromosome 17p11.2-p12 that results in reduced
expression of the PMP22 gene. CMT1A and HNPP
are reciprocal duplication/deletion syndromes that
originate from unequal crossover during germ cell
meiosis.2
Southern blots, pulsed-field gel electrophoresis
(PFGE), fluorescence in situ hybridization (FISH),
rapid real-time PCR gene dosage, and polymorphic
marker analysis are the currently used diagnostic
methods for CMT1A and HNPP detection.3 In a
recent study comparing real-time PCR with the other
methods currently used for the diagnosis of CMT, by
using a combination of junction fragment PCR, analysis
of microsatellite markers, and PFGE, 76 unrelated
patients with 17p12 duplication were identified. In
these patients, junction fragment PCR detected 63%
of cases of duplication, the microsatellite markers
method revealed 74%, while the combined use of
microsatellite markers and junction fragment PCR
revealed 91% of cases of CMT1A. PFGE detected
100% of the cases with duplication, even in the presence
of atypical 17p12 duplication. Real-time PCR detected
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PCR Diagnostic Strategy for CMT1A and HNPP
100% of the cases with CMT1A and was comparable
to PFGE. However, in contrast to PFGE, real-time
PCR does not need fresh blood, and minimizes
diagnosis time and cost.4 A conclusion might be made
that the previous methods are time-consuming, labor-
intensive, and have some significant limitations,
especially difficulties in interpretation of dosage for
different alleles.5
As reported in this issue of the Journal of the
Chinese Medical Association, Lin et al6 developed
allele-specific primers to amplify genomic DNA of
patients with CMT1A and HNPP, which provides a
rapid quantitative PCR method for determining gene
copy number for the identification of DNA duplication
or deletion occurring in CMT1A or HNPP. They
could identify the mutations by means of agarose gel
electrophoresis after PCR amplification without
restriction enzyme digestion from 33 (82.5%) of the
40 CMT1A and 19 (76.0%) of the 25 HNPP samples.
All CMT1A and HNPP patients had previously been
identified with microsatellite mapping. Stringently
specific primers were used to overcome the problem
of nonspecific amplification and provide a rapid,
all-or-none PCR product and efficient screening test
for CMT1A and HNPP. This new method is also
faster and easier than currently available methods.
The question has been raised whether the absence of
PCR products in some patients was related to technical
reasons in the CMT1 or HNPP assays or not, and the
design of primers for multiplex PCR has been
suggested for improving the detection rate.
Currently, mutations in multiple different genes
expressed in Schwann cells and neurons cause a variety
of overlapping clinical phenotypes of CMT and HNPP.
Recent studies have clarified the molecular pathways
involved in the pathogenesis of these disorders, and for
the first time provide rational treatment strategies for
the most common forms of CMT, especially CMT1
and HNPP.7 Taken together, results from these studies
support the concept that genetic causes of CMT serve
as a living microarray system to identify molecules
necessary for normal peripheral nervous system
function. When we can make sense of these microarrays,
we are likely to understand the pathogenesis and
develop rational therapies for CMT1A and HNPP.7
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